<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736202</url>
  </required_header>
  <id_info>
    <org_study_id>FLAME</org_study_id>
    <nct_id>NCT01736202</nct_id>
  </id_info>
  <brief_title>Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity</brief_title>
  <acronym>FLAME</acronym>
  <official_title>Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Center for Diabetes Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of type 2 diabetes is based on a combination of insulin resistance and beta&#xD;
      cell dysfunction. In the last years, elevated FFA were recognized as a key players in the&#xD;
      pathogenesis of insulin resistance and type 2 diabetes.&#xD;
&#xD;
      The study compares the acute effects of an oral lipid bolus on insulin sensitivity and&#xD;
      hepatic glucose metabolism in healthy humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dysregulation of lipid metabolism with increased levels of free fatty acids (FFA)&#xD;
      represents one key mechanism in the pathogenesis of insulin resistance, which contributes to&#xD;
      the development of type 2 diabetes (T2D). In most cases, dyslipidemia is related to obesity&#xD;
      and the metabolic syndrome. Not only skeletal muscle glucose uptake, but also hepatic glucose&#xD;
      fluxes are altered in insulin resistant states. In obese and T2D subjects, rates of&#xD;
      gluconeogenesis (GNG) are increased, but in obese normoglycemic subjects endogenous glucose&#xD;
      production (EGP) remains constant because of downregulation of glycogenolysis (GL). However,&#xD;
      in T2D subjects, both GNG and GL are elevated, contributing to fasting and postprandial&#xD;
      hyperglycemia. Therefore, elevated GNG rates may represent an early event in the&#xD;
      pathophysiology of insulin resistance and T2D.&#xD;
&#xD;
      Preliminary studies of our institute show that intravenous lipid infusion with subsequent&#xD;
      elevation of FFA results in increased GNG rates without alteration of EGP in lean,&#xD;
      non-diabetic subjects. In another recent study we investigated the effects of an oral fat&#xD;
      load on hepatic insulin sensitivity. As expected, we did not find any alterations in EGP;&#xD;
      however, rates of GNG and GL have not been assessed.&#xD;
&#xD;
      The aim of this study is to analyze the effects of an oral fat load with transiently elevated&#xD;
      levels of circulating lipids on hepatic glucose fluxes, especially GNG and GL, to elucidate&#xD;
      the role of dietary fat in the induction of insulin resistance in healthy humans.&#xD;
&#xD;
      In this randomized, controlled cross-over study, effects of oral palm oil and canola oil&#xD;
      ingestion will be investigated in young, healthy lean subjects. Hepatic glucose fluxes will&#xD;
      be assessed by two independent methods, in vivo magnet resonance spectroscopy (MRS) and the&#xD;
      deuterated water/acetaminophen method, which also allows for the determination of glycogen&#xD;
      cycling rates. Furthermore, hepatic phosphorus metabolites and liver fat content will be&#xD;
      monitored by MRS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of intervention on whole body insulin sensitivity</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of intervention on hepatic insulin sensitivity</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of intervention on rates of gluconeogenesis and glycogenolysis</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Palm oil orally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral fat load</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canola oil orally</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral fat load</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Water orally</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral water administration as control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>fat orally</intervention_name>
    <description>Oral ingestion of palm oil or canola oil or water at timepoint zero</description>
    <arm_group_label>Canola oil orally</arm_group_label>
    <arm_group_label>Palm oil orally</arm_group_label>
    <arm_group_label>Water orally</arm_group_label>
    <other_name>water orally</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy male and female subjects&#xD;
&#xD;
          -  age 20-40&#xD;
&#xD;
          -  BMI 20-25 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hyperlipidemia&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  allergy against paracetamol/palm oil/canola oil&#xD;
&#xD;
          -  contraindication for MRI investigations&#xD;
&#xD;
          -  anaemia&#xD;
&#xD;
          -  taking drugs influencing lipid or glucose metabolism, the immune system or&#xD;
             antihypertensive treatment&#xD;
&#xD;
          -  M. Meulengracht&#xD;
&#xD;
          -  Hepatitis/HIV&#xD;
&#xD;
          -  chronic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, Prof., M.D.</last_name>
    <role>Study Director</role>
    <affiliation>German Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Diabetes Center</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Kahl, M.D.</last_name>
      <phone>+492113382740</phone>
      <email>sabine.kahl@ddz.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Bettina Nowotny, M.D.</last_name>
      <phone>+492113382575</phone>
      <email>bettina.nowotny@ddz.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Kahl, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Diabetes Center</investigator_affiliation>
    <investigator_full_name>julia szendrödi</investigator_full_name>
    <investigator_title>Leader Clinical Research Center</investigator_title>
  </responsible_party>
  <keyword>oral fat</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

